A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Stopped Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population.

Conditions

• Atopic Dermatitis

Interventions

• DRUG: Tezepelumab
• OTHER: Placebo

Sponsor

Amgen

Collaborators

• [object Object]